New vaccine aims to fight rare abdominal cancer
NCT ID NCT07341360
First seen Jan 16, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This early-phase trial tests a cancer vaccine (Pseudovax) plus an immunotherapy drug (tislelizumab) in 10 adults with pseudomyxoma peritonei, a rare abdominal cancer that has returned or cannot be surgically removed. The vaccine targets tumors with a specific GNAS gene mutation, and the immunotherapy helps the immune system attack cancer cells. The main goals are to check safety and measure immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSEUDOMYXOMA PERITONEI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Oslo University Hospital HF, Radium
RECRUITINGOslo, Oslo, 0379, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.